EUVIMEDEUVIMED entdecken
Crossref

Serum Proteomic Signatures Before the Diagnosis of Rheumatoid Arthritis: Evolving Biologic Pathways and Specific Periods of Disease Development

Samir Rachid Zaim iD, Adam K Savage iD, Mark A Gillespie, Jazmine D Castillo, Christy Bennett, Troy R Torgerson, Lynne A Becker iD, Michael Mahler, LauraKay Moss, Marie L Feser, Jess D Edison, Ted R Mikuls iD und 3 weitere

Arthritis & Rheumatology · 2025-09 · 77 (9) · 1166-1178

DOI: 10.1002/art.43175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 13.05.2025. Verfasst von Samir Rachid Zaim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Allen Institute for Immunology, Seattle, Washington. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Anti-Citrullinated Protein Antibodies, Autoantibodies. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: NIAMS NIH HHS, Congressionally Directed Medical Research Programs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This longitudinal case‐control study evaluated serum proteomics before a clinical diagnosis of rheumatoid arthritis (RA) (ie, pre‐RA) to evaluate biologic pathways of disease development and inform prediction of timing of onset of future disease.

Methods

Patients (n = 213) meeting the 1987 American College of Rheumatology classification criteria for RA and matched controls without RA (n = 215) were identified in the Department of Defense Serum Repository. Serum samples from patients before and after RA diagnosis and controls were tested for RA‐related autoantibodies (anti–cyclic citrullinated peptide‐3 [anti‐CCP3] and rheumatoid factor [RF] isotypes IgM and IgA) and 197 proteins using a commercial platform (Olink). We applied linear mixed effect models to identify biomarkers distinguishing patients from controls before RA diagnosis and analyzed longitudinal patterns of enriched pathways; in addition, models were developed to classify the time of a sample in relationship to the time of RA diagnosis.

Results

Levels of anti‐CCP3, RFIgA, and RFIgM demonstrated the greatest differences between patients and controls ≤5 years before RA diagnosis. Longitudinal analyses identified 104 proteins that were differentially expressed between patients and controls; 60 proteins were differentially expressed ≤5 years before diagnosis, 42 proteins were differentially expressed within and before five years of diagnosis, and 2 proteins were differentially expressed >5 years before diagnosis. Kyoto Encyclopedia of Genes and Genomes analyses identified that these proteins were associated with 32 pathways, including 21 pathways that were enriched ≤5 years before diagnosis. Within the anti–citrullinated protein antibody–positive samples from before RA diagnosis and controls, a set of features classified if that sample was from a period

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAnti-Citrullinated Protein AntibodiesAutoantibodiesHumansMaleFemaleProteomicsMiddle AgedCase-Control StudiesBiomarkersRheumatoid FactorLongitudinal StudiesAdultAgedDisease ProgressionPeptides, Cyclic

Substanzen

BiomarkersRheumatoid FactorAnti-Citrullinated Protein AntibodiesAutoantibodiesPeptides, Cyclic

Autor:innen und Institutionen

  • Allen Institute for Immunology, Seattle, Washington.
  • Inova Diagnostics, San Diego, California.
  • University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Walter Reed National Military Medical Center and Uniformed Services University of the Health Sciences, Bethesda, Maryland.
  • University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska.

ORCID-Profile: Samir Rachid Zaim, Adam K Savage, Lynne A Becker, Ted R Mikuls, Kevin D Deane

Förderung

  • NIAMS NIH HHS
  • Congressionally Directed Medical Research Programs

Zitieren

APA

Rachid Zaim, S., Savage, A. K., Gillespie, M. A., Castillo, J. D., Bennett, C., Torgerson, T. R., Becker, L. A., Mahler, M., Moss, L., Feser, M. L., Edison, J. D., Mikuls, T. R., Holers, V. M., Li, X. J., & Deane, K. D. (2025). Serum Proteomic Signatures Before the Diagnosis of Rheumatoid Arthritis: Evolving Biologic Pathways and Specific Periods of Disease Development. Arthritis & Rheumatology, 77(9), 1166-1178. https://doi.org/10.1002/art.43175

Vancouver

Rachid Zaim S, Savage AK, Gillespie MA, Castillo JD, Bennett C, Torgerson TR, et al. Serum Proteomic Signatures Before the Diagnosis of Rheumatoid Arthritis: Evolving Biologic Pathways and Specific Periods of Disease Development. Arthritis & Rheumatology. 2025;77(9):1166-1178. doi:10.1002/art.43175

BibTeX
@article{RachidZaim2025,
  author = {Rachid Zaim, Samir and Savage, Adam K and Gillespie, Mark A and Castillo, Jazmine D and Bennett, Christy and Torgerson, Troy R and Becker, Lynne A and Mahler, Michael and Moss, LauraKay and Feser, Marie L and Edison, Jess D and Mikuls, Ted R and Holers, V Michael and Li, Xiao-Jun and Deane, Kevin D},
  title = {Serum Proteomic Signatures Before the Diagnosis of Rheumatoid Arthritis: Evolving Biologic Pathways and Specific Periods of Disease Development},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  volume = {77},
  number = {9},
  pages = {1166--1178},
  doi = {10.1002/art.43175}
}
Kostenlos starten →